China Unveils Action Plan to Boost Foreign Investment and Open Economy Further
The State Council of China has unveiled an ambitious “Action Plan to Promote the High-Level...
Simcere Pharmaceutical Reports 4.5% Revenue Growth in 2023 Amid Shifts in Profitability
Simcere Pharmaceutical Group (HKG: 2096), based in China, has released its 2023 financial performance report,...
Sinopharm and Fresenius Kabi Expand Partnership to Enhance Drug Distribution and Healthcare Services
China’s state-owned Sinopharm Group Co., Ltd. (HKG: 1099) has announced a new partnership with Germany’s...
Bayer and Thermo Fisher Partner to Develop Rapid Companion Diagnostics for Precision Oncology
Germany’s Bayer (NYSE: BAYE) has entered into a strategic partnership with U.S. life sciences leader...
iRegene’s NouvSight001 Gains Orphan Drug Designation for Retinitis Pigmentosa Treatment
Wuhan-based cell therapy innovator iRegene has secured Orphan Drug Designation (ODD) from the U.S. FDA...
BMS Reports Positive Phase III Results for Opdivo and Yervoy in Advanced HCC
Bristol Myers Squibb (BMS; NYSE: BMY) announced this week that its Phase III study evaluating...
China Resources Guangdong Pharmaceutical Partners with BD to Enhance Drug and Device Distribution in GBA
China Resources Guangdong Pharmaceutical Co., Ltd has entered into a strategic partnership with U.S.-based Becton,...
CAIR Launches CARES Copilot 1.0: A Revolutionary AI Chatbot for Medical Diagnosis and Treatment
The Centre for Artificial Intelligence and Robotics (CAIR), part of the Chinese Academy of Sciences...
VIVA Biotech Secures Licensing Deal with Lonza for Advanced Bispecific Antibody Technology
VIVA Biotech Holdings (HKG: 1873), a China-based Contract Research Organization (CRO), has entered into a...
Antengene’s ATG-022 Advances to Dose Expansion Phase in Phase II CLINCH Study for Solid Tumors
Antengene Corporation Ltd (HKG: 6996), a leading biopharmaceutical company based in China, has announced that...
CSPC Pharmaceutical Secures NMPA Approval for Clinical Study of SYS6023 in Advanced Solid Tumors
CSPC Pharmaceutical Group Ltd (HKG: 1093), a prominent China-based biopharmaceutical company, has received approval from...
3SBio Reports 13.8% Revenue Growth in 2023, Driven by Strong Sales of Core Biologics
3SBio Inc. (HKG: 1530), a leading China-based biopharmaceutical company, has reported its 2023 financial results,...
Innovent Biologics Reports 36.2% Revenue Growth in 2023, Highlights Robust Product Sales
Innovent Biologics Inc. (HKG: 1801), a China-based biotechnology firm, has released its 2023 financial report,...
Jiangsu Hengrui Receives NMPA Approval for Phase Ib/II Study of HRS2398 in Advanced Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Zuellig Pharma Expands Commercialization Deal for Karo Healthcare’s Lamisil in Asian Markets
Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement...
CSPC Pharmaceutical Gets NMPA Greenlight for SYH2039 Clinical Study in Advanced Malignant Tumors
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has received...
Novo Nordisk Invests RMB 4 Billion to Expand Sterile Manufacturing in Tianjin
Novo Nordisk (NYSE: NVO), a Denmark-based leader in diabetes care, has announced a substantial investment...
Suzhou Porton Biologics Partners with Kunshi Biotech to Advance Third-Generation CAR-M Therapy
Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...
China Expands Medical Service Pricing Reform with Three Additional Pilot Provinces
The National Healthcare Security Administration (NHSA) has announced an expansion of its medical services pricing...
Swiss Pharma Firm Carbogen Amcis Receives Brazil’s ANVISA GMP Certification for Shanghai Site
Carbogen Amcis, a Swiss firm specializing in active pharmaceutical ingredients (APIs) and pharmaceutical process development,...